Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
US FDA approves Menveo in a new single-vial presentation to help prevent disease caused by meningococcal bacteria serogroups A, C, Y, and W
The Menveo one-vial presentation now comes in a ready to use single vial giving healthcare providers a more convenient option.
-
GSK’s older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
Data showed overall vaccine efficacy against RSV-lower respiratory tract disease in adults aged 60 years and above
-
GSK to present updates on its industry-leading infectious disease portfolio at IDWeek 2022
GSK will share updates on its industry-leading infectious disease pipeline and portfolio with 33 abstracts accepted for IDWeek 2022.
-
US FDA approves BOOSTRIX for immunisation during pregnancy for the prevention of whooping cough in newborn infants
The US FDA has approved Boostrix for immunisation during the third trimester of pregnancy to help prevent pertussis (whooping cough).
-
GSK announces positive headline results from PERLA, the phase II trial of Jemperli (dostarlimab) plus chemotherapy in patients with metastatic non-squamous non-small cell lung cancer
The PERLA phase II trial is the largest global head-to-head trial of programmed death receptor-1 (PD-1) inhibitors in this population.
-
Iain Mackay, Chief Financial Officer, to retire from GSK, Julie Brown appointed as successor
The Board has selected Ms Julie Brown, currently Chief Operating and Financial Officer, Burberry Group plc, as successor to Iain Mackay.
-
Oncologic Drugs Advisory Committee to review Zejula overall survival data from the NOVA phase III trial in recurrent ovarian cancer
The US FDA will convene a meeting of the Oncologic Drugs Advisory Committee (ODAC) to discuss overall survival data from the Nova trial
-
GSK and Spero Therapeutics announce exclusive licence agreement for tebipenem HBr, a late-stage antibiotic that may treat complicated urinary tract infections
GSK has entered into an exclusive license agreement with Spero Therapeutics for tebipenem pivoxil HBr.
-
GSK and Microsoft, in collaboration with the Centre for Health and Disease Studies, launch disease surveillance project in Nepal
New partnership combines expertise across Biopharma and Tech sectors.
-
GSK launches Sustainable Procurement Programme for suppliers
From 2023, the company will require and support suppliers to take action on sustainability commitments.
-
Zejula (niraparib) shows durable and sustained long-term progression-free survival benefit in the PRIMA study of first-line platinum-responsive advanced ovarian cancer
GSK today announced long-term data from the phase III PRIMA study
-
GSK announces update on US FDA regulatory review of daprodustat in anaemia of chronic kidney disease
GSK today announced that the US FDA will convene a meeting of the Cardiovascular and Renal Drugs Advisory Committee to review daprodustat
-
WHO grants prequalification to GSK’s Mosquirix – the first and only approved malaria vaccine
An important step for rolling out the vaccine to children living in regions with moderate to high transmission.
-
GSK to highlight the latest advances in cancer research from across its portfolio and pipeline at ESMO
GSK will present new findings from across its diverse oncology portfolio and pipeline at the congress.
-
GSK Board changes
Elizabeth (Liz) McKee Anderson to join the Board as Non-Executive Director
-
US FDA accepts new drug application for GSK’s momelotinib for the treatment of myelofibrosis
Regulatory submission included data from the pivotal MOMENTUM phase III clinical trial
-
Statement: Zantac (ranitidine) U.S. litigation
Statement regarding U.S. Zantac (ranitidine) litigation
-
GSK completes acquisition of Affinivax, Inc.
GSK today announced it has completed the acquisition of Affinivax, Inc, a clinical-stage biopharmaceutical company based in Cambridge.
-
Statement: Zantac (ranitidine) litigation
Response to recent speculative commentary regarding U.S. Zantac litigation
-
GSK Announces Offer to Repurchase Exchangeable Senior Notes Due 2023
GSK Finance (No.3) plc, is offering to repurchase for cash any and all of its outstanding Exchangeable Senior Notes due 2023.
